Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. [electronic resource]
Producer: 20131031Description: 974-80 p. digitalISSN:- 1532-2157
- Adult
- Aged
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Hepatocellular -- drug therapy
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Female
- Humans
- Immunohistochemistry
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- PTEN Phosphohydrolase -- metabolism
- Phenylurea Compounds -- therapeutic use
- Phosphorylation
- Prognosis
- Ribosomal Protein S6 Kinases, 70-kDa -- metabolism
- Sorafenib
- Treatment Outcome
- Vascular Endothelial Growth Factor Receptor-2 -- metabolism
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.